Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment
- E. Lukasiewicz
- , M. Gorfine
- , L. S. Freedman
- , J. M. Pawlotsky
- , S. W. Schalm
- , C. Ferrari
- , S. Zeuzem
- , A. U. Neumann
- Bar-Ilan University
- The Gertner Institute
- Technion-Israel Institute of Technology
- Hôpital Henri Mondor
- Erasmus University Rotterdam
- University of Parma
- Saarland University
Research output: Contribution to journal › Article › peer-review
7
Scopus
citations